“In the last three scans, which I have every six weeks, they’re showing that there is no mestastasis (invasive cancer) anywhere in my body. [The doctors] I guess were quite blown away because they didn’t expect [the treatment] to be so quick or to be that complete.”
Today we’re sharing the story of Tom Howing, who took part in Forty Seven, Inc.’s CIRM-funded clinical trial that’s testing an innovative treatment for cancer.
The two-minute video below sums up Tom’s address to CIRM’s governing Board back in December. During his talk, he gave a personal perspective on his cancer diagnosis, the promising but ultimately disappointing results of standard anti-cancer treatments and the remarkable results he’s experienced from Forty Seven’s clinical trial.
Tom’s story is featured in our 2017 Annual Report (page 18), now available on our website.